Researcher Concludes That Pharmaceuticals Are A Market For Producing 'Lemons' And Serious Harm
Archives
All entries, chronologically...
A new multi-center study, including neurologists and neurosurgeons from the Perelman School of Medicine at the University of Pennsylvania, reveals that Deep Brain Stimulation (DBS) – a treatment for Parkinson’s disease (PD) patients with medication-resistant muscle movement impairment or tremors – can improve those symptoms and reduce medications for patients implanted with the device. The study appears Online First in Lancet Neurology.
Patients with Parkinson disease-related dementia appear to have increased brain atrophy in the hippocampal, temporal and parietal lobes and decreased prefrontal cortex volume compared to patients with Parkinson disease without dementia, according to a report in the December issue of Archives of Neurology, one of the JAMA/Archivesjournals. The study was conducted by Daniel Weintraub, M.D., of the Perelman School of Medicine, University of Pennsylvania, Philadelphia, and colleagues.
Before she could seek to convince the world that her computer model of a key brain circuit explains a fundamental, 80-year-old mystery of neuroscience with potential relevance to Parkinson’s disease, Stephanie Jones sought to convince Christopher Moore. The new Brown neuroscience professors are now close collaborators, but when they first started talking about the beta oscillations of the cortex, Moore thought Jones was plain wrong, if not a bit nuts.
Computer analysis of brain scans could help predict how severe the future illness course of a patient with psychosis will be, according to research funded by the Medical Research Council and the Wellcome Trust. The findings could allow doctors to make more accurate decisions about how best to treat patients. Psychosis is a condition that affects people’s minds, altering the way they think, feel and behave. It can be accompanied by hallucinations and delusions. The most common forms are part of mental health conditions such as schizophrenia and bipolar disorder, but symptoms of psychosis can also occur in conditions such as Parkinson’s disease and alcohol or drug abuse.
While deep brain stimulation has gained recognition by referring physicians as a treatment for Parkinson’s disease and other movement disorders, just half of the patients they recommend are appropriate candidates to begin this relatively new therapy immediately, researchers at Cedars-Sinai Medical Center in Los Angeles and The Mount Sinai Medical Center in New York say.
One decade after receiving implants that stimulate areas of their brains, patients with Parkinson’s disease (PD) appear to sustain improvement in motor function, although part of the initial benefit wore off mainly because of progressive loss of benefit in other functions, according to a report published Online First by Archives of Neurology, one of the JAMA/Archives journals.
People who abused methamphetamine or other amphetamine-like stimulants were more likely to develop Parkinson’s disease than those who did not, in a new study from the Centre for Addiction and Mental Health (CAMH). The researchers examined almost 300,000 hospital records from California covering 16 years. Patients admitted to hospital for methamphetamine or amphetamine-use disorders had a 76 per cent higher risk of developing Parkinson’s disease compared to those with no disorder.
Tom Keilen could not grab a glass of water without spilling it all over himself. Plagued with uncontrollable tremors at just 57 years old, the Michigan resident was fighting a battle against an aggressive case of Parkinson’s disease. He could not work at his job as a plastering contractor. His arms would flail uncontrollably, and the medications usually prescribed for Parkinson’s did not help enough. Keilen sought help at the University of Michigan, where after an extensive assessment, he underwent a deep brain stimulation surgery. Included in this report is a video discussion of deep brain stimulation along with an interview of Tom.
A new study of the brain’s master circadian clock — known as the suprachiasmatic nucleus, or SCN — reveals that a key pattern of rhythmic neural activity begins to decline by middle age. The study, whose senior author is UCLA Chancellor Gene Block, may have implications for the large number of older people who have difficulty sleeping and adjusting to time changes. The study results were published July 13 in the Journal of Neuroscience, the journal of the Society for Neuroscience.
Half of patients with Parkinson’s disease (PD) and psychosis receive prescriptions for anti-psychotic (AP) agents, including drugs that have the potential to worsen Parkinson symptoms, and the frequency of use of these agents has not changed since a warning about using these drugs in patients with dementia and PD was issued, according to a report in the July issue of Archives of Neurology, one of the JAMA/Archives journals. The research was conducted by Daniel Weintraub, M.D., from the University of Pennsylvania, and colleagues.
